Brokerages Set Paratek Pharmaceuticals Inc (PRTK) Target Price at $37.33

Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) have been given a consensus rating of “Buy” by the nine brokerages that are presently covering the company. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $38.38.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Thursday. HC Wainwright upped their price target on shares of Paratek Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Robert W. Baird reiterated an “outperform” rating and set a $40.00 price objective on shares of Paratek Pharmaceuticals in a research note on Tuesday, April 4th. BTIG Research boosted their price objective on shares of Paratek Pharmaceuticals from $47.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, April 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $32.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, March 30th.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/04/21/paratek-pharmaceuticals-inc-prtk-receives-37-33-average-pt-from-analysts-updated.html.

In other Paratek Pharmaceuticals news, CFO Douglas W. Pagan sold 3,405 shares of the stock in a transaction on Monday, February 6th. The shares were sold at an average price of $15.09, for a total transaction of $51,381.45. Following the transaction, the chief financial officer now directly owns 58,983 shares of the company’s stock, valued at $890,053.47. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Evan Loh sold 3,106 shares of the stock in a transaction on Monday, February 6th. The shares were sold at an average price of $15.09, for a total transaction of $46,869.54. Following the transaction, the chief operating officer now directly owns 102,873 shares in the company, valued at $1,552,353.57. The disclosure for this sale can be found here. Insiders have sold 11,511 shares of company stock worth $173,701 over the last three months. 2.00% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of PRTK. Wells Fargo & Company MN boosted its stake in shares of Paratek Pharmaceuticals by 196.5% in the third quarter. Wells Fargo & Company MN now owns 8,005 shares of the specialty pharmaceutical company’s stock worth $104,000 after buying an additional 5,305 shares during the period. Ardsley Advisory Partners acquired a new stake in shares of Paratek Pharmaceuticals during the third quarter worth approximately $130,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Paratek Pharmaceuticals during the fourth quarter worth approximately $158,000. Ellington Management Group LLC acquired a new stake in shares of Paratek Pharmaceuticals during the fourth quarter worth approximately $179,000. Finally, Croft Leominster Inc. acquired a new stake in shares of Paratek Pharmaceuticals during the third quarter worth approximately $188,000. Institutional investors and hedge funds own 76.06% of the company’s stock.

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded down 0.23% on Tuesday, reaching $21.55. The company had a trading volume of 468,939 shares. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $25.00. The company’s 50-day moving average is $18.64 and its 200-day moving average is $15.06. The company’s market capitalization is $523.36 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Thursday, March 2nd. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.17. The business earned $0.03 million during the quarter.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

5 Day Chart for NASDAQ:PRTK

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply